Cancer Treatment Today

A recent review by Anestis et al concluded: ” he value of AR as a biomarker and therapeutic target in breast cancer remains elusive. The contradictory results are due to the heterogeneity of the disease, as well as to the fact that there is no well-defined cut-off value of AR positivity. The dual role of AR as either a suppressor or inducer of tumor progression enables both androgens and antiandrogens to be used in potential therapeutic regiments. Since clinical trials have shown promising results, research should focus on the identification of novel biomarkers in order to stratify patient subgroups that will benefit the most from AR-targeted therapies.:

Liu, C. Y., Lau, K. Y., Hsu, C. C., Chen, J. L., Lee, C. H., Huang, T. T., Tseng, L. M. (2017). Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PloS one, 12(12), e0189007. doi:10.1371/journal.pone.0189007

Rampurwala, M., Wisinski, K. B., & O’Regan, R. (2016). Role of the androgen receptor in triple-negative breast cancer. Clinical advances in hematology & oncology : H&O, 14(3), 186193.
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Cortes, J. (2018). Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(9), 884890. doi:10.1200/JCO.2016.71.3495

Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A. The Androgen Receptor in Breast Cancer. Front Endocrinol (Lausanne). 2018;9:492. Published 2018 Aug 28. doi:10.3389/fendo.2018.00492

Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights. Molecules. 2020;25(2):358. Published 2020 Jan 15. doi:10.3390/molecules25020358